- Home
- YUMC vs GMAB Comparison
YUMC vs GMAB Comparison
Compare YUMC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YUMC
- GMAB
- Stock Information
- Founded
- YUMC 1987
- GMAB 1999
- Country
- YUMC China
- GMAB Denmark
- Employees
- YUMC N/A
- GMAB N/A
- Industry
- YUMC Restaurants
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- YUMC Consumer Discretionary
- GMAB Health Care
- Exchange
- YUMC Nasdaq
- GMAB Nasdaq
- Market Cap
- YUMC 15.6B
- GMAB 17.4B
- IPO Year
- YUMC N/A
- GMAB N/A
- Fundamental
- Price
- YUMC $43.32
- GMAB $28.62
- Analyst Decision
- YUMC Buy
- GMAB Strong Buy
- Analyst Count
- YUMC 1
- GMAB 7
- Target Price
- YUMC $60.00
- GMAB $41.17
- AVG Volume (30 Days)
- YUMC 1.3M
- GMAB 2.6M
- Earning Date
- YUMC 11-04-2025
- GMAB 11-06-2025
- Dividend Yield
- YUMC 2.23%
- GMAB N/A
- EPS Growth
- YUMC 6.57
- GMAB 77.72
- EPS
- YUMC 2.40
- GMAB 21.62
- Revenue
- YUMC $11,569,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- YUMC $5.94
- GMAB $24.92
- Revenue Next Year
- YUMC $5.73
- GMAB $15.97
- P/E Ratio
- YUMC $17.98
- GMAB $12.96
- Revenue Growth
- YUMC 3.29
- GMAB 32.97
- 52 Week Low
- YUMC $41.00
- GMAB $17.24
- 52 Week High
- YUMC $53.99
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- YUMC 46.22
- GMAB 39.86
- Support Level
- YUMC $43.03
- GMAB $28.08
- Resistance Level
- YUMC $46.08
- GMAB $29.35
- Average True Range (ATR)
- YUMC 0.96
- GMAB 0.65
- MACD
- YUMC -0.10
- GMAB -0.27
- Stochastic Oscillator
- YUMC 11.80
- GMAB 24.77
About YUMC Yum China Holdings Inc.
With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.